Brinker Capital Investments’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Brinker Capital Investments’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-29,261	Closed	-$1.27M	–	1774
2023 Q3	$1.27M	Buy	29,261 +6,944	+31%	+$248K	0.02%	817
2023 Q2	$806K	Sell	22,317 -729	-3%	-$30K	0.01%	1035
2023 Q1	$857K	Buy	23,046 +359	+2%	+$16.1K	0.01%	942
2022 Q4	$1.03M	Buy	22,687 +5,925	+35%	+$383K	0.02%	721
2022 Q3	$1.17M	Buy	16,762 +2,692	+19%	+$199K	0.02%	647
2022 Q2	$945K	Buy	14,070 +6,882	+96%	+$438K	0.02%	767
2022 Q1	$591K	Buy	+7,188	New	+$735K	0.01%	990

Other funds holding MRTX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return

Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Brinker Capital Investments's MRTX Position: Q4 2023 in Review

Brinker Capital Investments sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 29,261 shares — an estimated $1.27M sold.

Brinker Capital Investments first reported a position in MRTX in Q1 2022 and held it in 7 quarters. The position peaked at $1.27M in Q3 2023. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

Brinker Capital Investments reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Brinker Capital Investments sold 29,261 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $1.27M.
Brinker Capital Investments first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2022 and held it in 7 quarters.
Brinker Capital Investments's Mirati Therapeutics, Inc. Common Stock position peaked at $1.27M in Q3 2023.
217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Brinker Capital Investments's 13F filing for Q4 2023, filed 31 Jul 2025.